Evidence map›Paper›PMID 29286881›Full record

ArticlePlant signaling & behavior2018

Daurichromenic acid and grifolic acid: Phytotoxic meroterpenoids that induce cell death in cell culture of their producer Rhododendron dauricum.

Futoshi Taura, Miu Iijima, Fumiya Kurosaki

Open access · bronzeAbstract read
In one paragraph

Article in Plant signaling & behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Supercritical COPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Review
  4. Antimicrobial, Probiotic, and Immunomodulatory Potential ofAntibiotics (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Metabolic Engineering ofMetabolites · 2022
    Article
  7. Review
  8. HarnessingJournal of natural products · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Futoshi Tauraa Graduate School of Medicine and Pharmaceutical Sciences for Research , University of Toyama , Sugitani , Toyama , Japan.ORCID 0000-0001-6551-123X
Miu Iijimaa Graduate School of Medicine and Pharmaceutical Sciences for Research , University of Toyama , Sugitani , Toyama , Japan.
Fumiya Kurosakia Graduate School of Medicine and Pharmaceutical Sciences for Research , University of Toyama , Sugitani , Toyama , Japan.
University of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daurichromenic acid (DCA) is a meroterpenoid with anti-HIV activities that is isolated from Rhododendron dauricum L. We recently reported that DCA is biosynthesized and accumulated in the apoplast of glandular scales attached on the surface of young leaves of R. dauricum. In the present study, we confirmed that a cell suspension culture of R. dauricum could not produce DCA and its precursor grifolic acid even after elicitation with methyl jasmonate and β-cyclodextrin. In addition, exogenous supplementation of DCA and grifolic acid effectively induced cell death in the same culture, with apoptosis-associated phenomena such as cytoplasmic shrinkage, chromatin condensation, and genomic DNA degradation. These findings suggested that DCA and grifolic acid are phytotoxic metabolites that have to be sequestered in the apoplast to avoid self-poisoning.

Indexed as

Cell DeathCells, CulturedChromansRhododendronSesterterpenesChromansdaurichromenic acidgrifolic acidSesterterpenesdaurichromenic acidgrifolic acidmeroterpenoidphytotoxic activityRhododendron dauricum

Identifiers

PMID29286881
PMCPMC5790407
OpenAlexW2777798283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.